Comparative Pharmacology
Head-to-head clinical analysis: DILANTIN 125 versus ESLICARBAZEPINE ACETATE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: DILANTIN 125 versus ESLICARBAZEPINE ACETATE.
DILANTIN-125 vs ESLICARBAZEPINE ACETATE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Phenytoin stabilizes neuronal membranes by promoting voltage-gated sodium channel inactivation, reducing high-frequency neuronal firing and seizure propagation.
Eslicarbazepine acetate is a voltage-gated sodium channel blocker that stabilizes the inactive state of sodium channels, reducing high-frequency repetitive firing of neurons. It also modulates T-type calcium channels and enhances slow inactivation of sodium channels.
300-400 mg per day orally in divided doses (e.g., 100 mg three times daily); loading dose 1 g orally divided into three doses given at 2-hour intervals, then 100 mg every 6-8 hours for first 24 hours.
400 mg orally once daily, titrated to a maintenance dose of 800-1200 mg once daily.
None Documented
None Documented
Clinical Note
moderateEslicarbazepine acetate + Estrone sulfate
"The serum concentration of Estrone sulfate can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateEslicarbazepine acetate + Aripiprazole
"The serum concentration of Aripiprazole can be decreased when it is combined with Eslicarbazepine acetate."
Clinical Note
moderateCyclophosphamide + Eslicarbazepine acetate
"The metabolism of Eslicarbazepine acetate can be decreased when combined with Cyclophosphamide."
Clinical Note
moderateTerminal half-life: 7-42 hours (mean 22 hours) in adults; dose-dependent due to saturable metabolism. Steady-state reached in 7-10 days.
Terminal half-life of eslicarbazepine is 13-20 hours (mean ~14 hours), supporting once-daily dosing.
Renal: 70% as metabolites (mainly HPPA glucuronide and sulfate), 5-10% as unchanged drug. Fecal: 30% (minor).
Renal: ~90% (as glucuronide conjugates and unchanged drug; ~30% as eslicarbazepine acetate, ~60% as eslicarbazepine). Fecal: <1%. Biliary: negligible.
Category C
Category C
Anticonvulsant
Anticonvulsant
Phenytoin + Eslicarbazepine acetate
"The serum concentration of Eslicarbazepine acetate can be decreased when it is combined with Phenytoin."